MA38391A1 - Dérivés de pyridinyl et triazolone pyridinyl de fusion - Google Patents

Dérivés de pyridinyl et triazolone pyridinyl de fusion

Info

Publication number
MA38391A1
MA38391A1 MA38391A MA38391A MA38391A1 MA 38391 A1 MA38391 A1 MA 38391A1 MA 38391 A MA38391 A MA 38391A MA 38391 A MA38391 A MA 38391A MA 38391 A1 MA38391 A1 MA 38391A1
Authority
MA
Morocco
Prior art keywords
pyridinyl
compounds
formula
triazolone
fusion
Prior art date
Application number
MA38391A
Other languages
English (en)
Other versions
MA38391B1 (fr
Inventor
John David Lawson
Mark Sabat
Nicholas Scorah
Christopher Smith
Phong H Vu
Haixia Wang
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of MA38391A1 publication Critical patent/MA38391A1/fr
Publication of MA38391B1 publication Critical patent/MA38391B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés de formule 1 ou des sels pharmaceutiquement acceptables de ceux-ci, dans la formule, r1, r2, r3, et r4 sont tels que définis dans la description. Cette invention concerne également des matières et des procédés permettant de préparer les composés de formule 1, des compositions pharmaceutiques contenant ces composés, ainsi que leur utilisation pour traiter des réactions d'hypersensibilité de type i, des maladies auto-immunes, des troubles inflammatoires, le cancer, des troubles proliférants bénins, et d'autres états associés à la tyrosine kinase de bruton (btk).
MA38391A 2013-03-11 2014-03-10 Dérivés de pyridinyl et triazolone pyridinyl de fusion MA38391B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776445P 2013-03-11 2013-03-11
PCT/US2014/022801 WO2014164558A1 (fr) 2013-03-11 2014-03-10 Dérivés de pyridinyl et triazolone pyridinyl de fusion

Publications (2)

Publication Number Publication Date
MA38391A1 true MA38391A1 (fr) 2018-01-31
MA38391B1 MA38391B1 (fr) 2018-09-28

Family

ID=50543655

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38391A MA38391B1 (fr) 2013-03-11 2014-03-10 Dérivés de pyridinyl et triazolone pyridinyl de fusion

Country Status (43)

Country Link
US (4) US9402841B2 (fr)
EP (2) EP3235814B1 (fr)
JP (2) JP6271700B2 (fr)
KR (1) KR102300612B1 (fr)
CN (1) CN105121427B (fr)
AP (1) AP2015008646A0 (fr)
AR (1) AR095198A1 (fr)
AU (1) AU2014249248B2 (fr)
BR (1) BR112015020264B1 (fr)
CA (1) CA2899948C (fr)
CL (1) CL2015002370A1 (fr)
CR (1) CR20150470A (fr)
CY (1) CY1119356T1 (fr)
DK (1) DK2970202T3 (fr)
DO (1) DOP2015000184A (fr)
EA (1) EA028584B1 (fr)
EC (1) ECSP15042779A (fr)
ES (2) ES2714166T3 (fr)
GE (1) GEP201706778B (fr)
HK (1) HK1245256B (fr)
HR (1) HRP20170622T1 (fr)
HU (1) HUE032720T2 (fr)
IL (1) IL240353B (fr)
JO (1) JO3377B1 (fr)
LT (1) LT2970202T (fr)
MA (1) MA38391B1 (fr)
ME (1) ME02693B (fr)
MX (1) MX364527B (fr)
MY (1) MY183927A (fr)
PE (1) PE20151889A1 (fr)
PH (1) PH12015502046B1 (fr)
PL (1) PL2970202T3 (fr)
PT (1) PT2970202T (fr)
RS (1) RS55879B1 (fr)
SG (1) SG11201506112QA (fr)
SI (1) SI2970202T1 (fr)
SM (1) SMT201700218T1 (fr)
TN (1) TN2015000342A1 (fr)
TW (1) TWI637950B (fr)
UA (1) UA114944C2 (fr)
UY (1) UY35376A (fr)
WO (1) WO2014164558A1 (fr)
ZA (1) ZA201505996B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
CN104447530A (zh) * 2014-12-11 2015-03-25 苏州欧凯医药技术有限公司 4-甲基-2,6-二羧基吡啶的制备方法
SG11201704808VA (en) 2014-12-18 2017-07-28 Principia Biopharma Inc Treatment of pemphigus
WO2016210165A1 (fr) 2015-06-24 2016-12-29 Principia Biopharma Inc. Inhibiteurs de la tyrosine kinase
EA039213B1 (ru) * 2015-12-24 2021-12-17 Такеда Фармасьютикал Компани Лимитед Сокристалл, способ его получения и лекарственное средство, содержащее сокристалл
DK3402503T3 (da) * 2016-01-13 2020-12-21 Acerta Pharma Bv Terapeutiske kombinationer af et antifolat og en btk-hæmmer
DK3436447T3 (da) 2016-03-31 2021-09-13 Takeda Pharmaceuticals Co Isoquinolinyl-triazolon-komplekser
CN115054586B (zh) 2016-06-29 2024-08-02 普林斯匹亚生物制药公司 改性的释放制剂
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
KR102459858B1 (ko) * 2019-04-02 2022-10-27 연세대학교 산학협력단 신규 화합물 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 조성물
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US20210106584A1 (en) 2019-10-14 2021-04-15 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US11814390B2 (en) 2020-01-22 2023-11-14 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
JP7545570B2 (ja) 2020-08-14 2024-09-04 ノバルティス アーゲー ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2025116652A1 (fr) * 2023-11-30 2025-06-05 주식회사 지엔티파마 Composition et méthode de traitement de maladies auto-immunes

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5733849A (en) * 1996-03-15 1998-03-31 Rohm And Haas Company Halopyridyl triazolinone herbicides and herbicidal use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ATE269295T1 (de) 1998-04-17 2004-07-15 Parker Hughes Inst Btk inhibitoren und verfahren zur identifizierung und verwendung
WO2002022605A1 (fr) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
WO2002050071A1 (fr) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Inhibiteurs thiazolyl des tyrosine kinases de la famille tec
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
SI2035396T1 (sl) * 2006-05-25 2014-08-29 Synta Pharmaceuticals Corp. Triazolne spojine, ki modulirajo aktivnost HSP90
BRPI0713736A2 (pt) 2006-06-20 2014-11-18 Hoffmann La Roche Derivados de tetralina e indano e emprego destes
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
SG10202107066WA (en) 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JP5643105B2 (ja) 2007-12-14 2014-12-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規イミダゾ［１，２−ａ］ピリジン及びイミダゾ［１，２−ｂ］ピリダジン誘導体
PL2242749T3 (pl) 2008-02-05 2013-09-30 Hoffmann La Roche Nowe pirydynony i pirydazynony
PH12012502374A1 (en) 2008-06-24 2014-11-12 Hoffmann La Roche Novel substituted pyridin-2-ones and pyridazin-3-ones
PE20110164A1 (es) 2008-07-02 2011-03-28 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de quinasa
WO2010006947A1 (fr) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Nouvelles phényl-imidazopyridines et pyridazines
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
WO2010068788A1 (fr) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amides hétérocycliques en tant qu'inhibiteurs de la btk
WO2010068810A2 (fr) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amides substitués, et leurs procédés de production et d'utilisation
JP2013526546A (ja) 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
WO2011153553A2 (fr) 2010-06-04 2011-12-08 The Regents Of The University Of California Méthodes et compositions pour l'inhibition de kinases
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
JP5947307B2 (ja) 2010-10-20 2016-07-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としての置換６−アミノ−ニコチンアミド
JP2013544321A (ja) 2010-11-10 2013-12-12 エスティーシー． ユーエヌエム ゼロ原子価金属粒子用エアロゾル還元／膨張合成（ａ−ｒｅｓ）
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج

Also Published As

Publication number Publication date
TW201522328A (zh) 2015-06-16
CN105121427A (zh) 2015-12-02
IL240353A0 (en) 2015-09-24
SMT201700218T1 (it) 2017-07-18
BR112015020264A2 (pt) 2017-07-18
PE20151889A1 (es) 2015-12-26
KR102300612B1 (ko) 2021-09-09
US10307414B2 (en) 2019-06-04
AP2015008646A0 (en) 2015-08-31
EP2970202B1 (fr) 2017-02-01
IL240353B (en) 2018-11-29
RS55879B1 (sr) 2017-08-31
NZ710852A (en) 2020-12-18
US20190224190A1 (en) 2019-07-25
PT2970202T (pt) 2017-05-03
EP3235814B1 (fr) 2018-12-12
US9801872B2 (en) 2017-10-31
MA38391B1 (fr) 2018-09-28
WO2014164558A1 (fr) 2014-10-09
MX364527B (es) 2019-04-30
MX2015011533A (es) 2016-02-03
CL2015002370A1 (es) 2016-03-11
JO3377B1 (ar) 2019-03-13
JP6462842B2 (ja) 2019-01-30
JP6271700B2 (ja) 2018-01-31
HRP20170622T1 (hr) 2017-06-30
ES2624439T3 (es) 2017-07-14
PL2970202T3 (pl) 2017-08-31
AU2014249248B2 (en) 2017-08-17
CA2899948C (fr) 2021-11-16
CY1119356T1 (el) 2018-02-14
HK1220183A1 (en) 2017-04-28
UY35376A (es) 2014-10-31
US20160310483A1 (en) 2016-10-27
TWI637950B (zh) 2018-10-11
DK2970202T3 (en) 2017-05-08
CN105121427B (zh) 2018-04-10
PH12015502046B1 (en) 2019-01-23
KR20150126687A (ko) 2015-11-12
ES2714166T3 (es) 2019-05-27
LT2970202T (lt) 2017-06-12
EP3235814A1 (fr) 2017-10-25
JP2016512515A (ja) 2016-04-28
TN2015000342A1 (en) 2017-01-03
ME02693B (fr) 2017-10-20
JP2018076357A (ja) 2018-05-17
DOP2015000184A (es) 2015-11-30
MY183927A (en) 2021-03-17
CA2899948A1 (fr) 2014-10-09
US9402841B2 (en) 2016-08-02
HUE032720T2 (en) 2017-10-30
SG11201506112QA (en) 2015-09-29
AU2014249248A1 (en) 2015-08-20
EP2970202A1 (fr) 2016-01-20
HK1245256B (en) 2019-09-27
BR112015020264B1 (pt) 2021-03-02
ZA201505996B (en) 2016-11-30
ECSP15042779A (es) 2017-08-31
EA201591686A1 (ru) 2015-12-30
GEP201706778B (en) 2017-11-27
EA028584B1 (ru) 2017-12-29
CR20150470A (es) 2016-01-11
US20140256734A1 (en) 2014-09-11
UA114944C2 (uk) 2017-08-28
US20180015083A1 (en) 2018-01-18
SI2970202T1 (sl) 2017-07-31
AR095198A1 (es) 2015-09-30
PH12015502046A1 (en) 2016-01-18

Similar Documents

Publication Publication Date Title
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA47079B1 (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA38138A1 (fr) Dérivés inédits de quinolone
WO2019035864A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA41179A (fr) Composés inhibiteurs de parg
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA37831A1 (fr) Dérivés d'azaindole agissant comme inhibiteur de pi3k
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA44948A1 (fr) Inhibiteurs de bace 1
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA46268A (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
MA43313B1 (fr) Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase